Personalized mRNA cancer vaccine shows promise in extending lifespan in melanoma trial
(NEW YORK) -- Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma.The individualized vaccine, when paired with the existing immunotherapy, Keytruda, is the first and only combination regimen that demonstrated success in potentially extending melanoma patients' lifespans.In Phase 3 trials, the regimen significantly reduced the risk of cancer returning or spreading. The trial was conducted among patients […]
